These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 9527771)

  • 1. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
    Hertogs K; de Béthune MP; Miller V; Ivens T; Schel P; Van Cauwenberge A; Van Den Eynde C; Van Gerwen V; Azijn H; Van Houtte M; Peeters F; Staszewski S; Conant M; Bloor S; Kemp S; Larder B; Pauwels R
    Antimicrob Agents Chemother; 1998 Feb; 42(2):269-76. PubMed ID: 9527771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
    Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
    J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.
    Weber J; Vazquez AC; Winner D; Rose JD; Wylie D; Rhea AM; Henry K; Pappas J; Wright A; Mohamed N; Gibson R; Rodriguez B; Soriano V; King K; Arts EJ; Olivo PD; Quiñones-Mateu ME
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3729-42. PubMed ID: 21628544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.
    Chang S; Zhuang D; Li J; Liu S; Li H; Han J; Li L; Liu Y; Bao Z; Li T; Song H; Zhang W
    Int J Infect Dis; 2015 Aug; 37():86-92. PubMed ID: 26117343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
    Robinson LH; Gale CV; Kleim JP
    J Virol Methods; 2002 Jul; 104(2):147-60. PubMed ID: 12088824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
    García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
    Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
    Yu M; Kabat W; Wang J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.
    García-Lerma JG; Heneine W
    J Clin Virol; 2001 Jun; 21(3):197-212. PubMed ID: 11397656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity.
    de la Carrière LC; Paulous S; Clavel F; Mammano F
    J Virol; 1999 Apr; 73(4):3455-9. PubMed ID: 10074202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
    Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
    Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.
    Kellam P; Larder BA
    Antimicrob Agents Chemother; 1994 Jan; 38(1):23-30. PubMed ID: 8141575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.
    Saladini F; Giannini A; Boccuto A; Vicenti I; Zazzi M
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28303602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance.
    Wu S; Yan P; Yan Y; Qiu L; Xie M
    Arch Virol; 2015 Jun; 160(6):1385-95. PubMed ID: 25795166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.